Skip to main content
. 2020 Oct 30;12(11):3200. doi: 10.3390/cancers12113200

Figure 2.

Figure 2

Schematic representation of the transfer of epidermal growth factor receptor, epidermal growth factor, amphiregulin or epiregulin from EVs to recipient cells of the immune system, tumour microenvironment or cells at metastatic sites. This EV-meditated transfer of EGFR or EGFR ligands has been shown to modulate the immune system, promote angiogenesis, metastasis and osteoclastogenesis in cancer.